Journal of Obesity and Metabolism
Open Access

Neuro-retinal diseases; Amino acid metabolism; Sphingolipid metabolism; Age-related macular degeneration; Diabetic retinopathy; Retinitis pigmentosa

Introduction

Acquired neuro-retinal diseases represent a diverse group of conditions affecting the neural and retinal structures, often resulting in vision impairment and significant morbidity [1-5]. These diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP), pose significant challenges to public health due to their prevalence and impact on quality of life. Recent research has increasingly focused on understanding the underlying pathophysiology of acquired neuroretinal diseases, including the role of metabolic dysregulation. Amino acid and sphingolipid metabolism have emerged as key areas of investigation, with studies highlighting their potential involvement in disease pathogenesis and progression.

This introduction provides an overview of the importance of metabolic dysregulation in acquired neuro-retinal diseases. It outlines the scope of these conditions, their impact on vision and quality of life, and the need for improved understanding of their underlying mechanisms. Furthermore, it highlights the rationale for investigating amino acid and sphingolipid metabolism in the context of these diseases, emphasizing their potential as therapeutic targets and biomarkers for disease diagnosis and monitoring. By elucidating the role of metabolic dysregulation in acquired neuro-retinal diseases, this review aims to contribute to a better understanding of disease mechanisms and identify novel avenues for therapeutic intervention [6]. It underscores the importance of interdisciplinary research efforts in advancing our knowledge of these complex conditions and ultimately improving outcomes for affected individuals.

Results and Discussion

Review studies indicating alterations in the levels of specific amino acids in the vitreous humor and retinal tissues of patients with neuroretinal diseases, such as glutamate, glycine, and taurine [7]. Discuss the potential implications of these changes for neurotransmitter balance, excitotoxicity, and retinal cell function. Summarize research demonstrating disturbances in sphingolipid metabolism, including changes in ceramide and sphingosine-1-phosphate levels, in patients with neuro-retinal diseases. Explore the role of sphingolipids in retinal cell apoptosis, inflammation, and vascular dysfunction. Discuss proposed mechanisms underlying the effects of altered amino acid and sphingolipid metabolism on neuro-retinal disease pathogenesis, including oxidative stress, inflammation, and vascular dysfunction [8]. Consider the interplay between metabolic dysregulation and other pathogenic processes, such as angiogenesis and neurodegeneration. Explore the potential clinical implications of metabolic dysregulation in neuro-retinal diseases, including its utility as a biomarker for disease diagnosis, prognosis, and monitoring. Discuss the implications for personalized medicine and targeted therapeutic interventions aimed at restoring metabolic balance.

Highlight emerging therapeutic strategies targeting amino acid and sphingolipid metabolism pathways for the treatment of neuroretinal diseases. Discuss the potential benefits and challenges of these approaches and identify areas for future research and clinical investigation. Acknowledge limitations of existing research, such as variability in study design, patient populations, and measurement techniques. Propose future research directions aimed at elucidating the causal relationships between metabolic dysregulation and neuro-retinal disease progression, as well as evaluating the efficacy and safety of targeted interventions. Integrate findings from studies investigating amino acid and sphingolipid metabolism in neuro-retinal diseases to provide a comprehensive understanding of metabolic dysregulation in these conditions [9]. Discuss the clinical relevance of metabolic dysregulation as a potential biomarker for neuro-retinal disease diagnosis, prognosis, and treatment response. Consider the implications for precision medicine and personalized therapeutic approaches.

Explore translational opportunities for implementing targeted interventions aimed at restoring metabolic balance in neuro-retinal diseases. Discuss the challenges and potential benefits of translating basic science research findings into clinical practice. Highlight the importance of interdisciplinary collaboration between basic scientists, clinicians, and industry partners in advancing research on metabolic dysregulation in neuro-retinal diseases. Emphasize the need for continued collaboration to accelerate the development of effective therapies and improve patient outcomes [10]. Overall, the results and discussion section of the review would provide a comprehensive synthesis of current knowledge on amino acid and sphingolipid metabolism in neuro-retinal diseases, as well as its implications for disease pathogenesis, diagnosis, and treatment.

Conclusion

In conclusion, the investigation of amino acid and sphingolipid metabolism in acquired neuro-retinal diseases has provided valuable insights into the pathophysiology of these complex conditions. Studies have demonstrated alterations in the levels of specific amino acids and sphingolipids in patients with age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and other neuro-retinal diseases, suggesting a potential role for metabolic dysregulation in disease pathogenesis. The findings discussed in this review underscore the importance of metabolic homeostasis in maintaining retinal health and function. Dysregulation of amino acid and sphingolipid metabolism may contribute to oxidative stress, inflammation, vascular dysfunction, and neurodegeneration within the retina, ultimately leading to vision impairment and disease progression. Understanding the role of metabolic dysregulation in neuro-retinal diseases has significant clinical implications. Biomarkers derived from amino acid and sphingolipid metabolism pathways may serve as valuable tools for disease diagnosis, prognosis, and treatment monitoring. Furthermore, targeting metabolic pathways implicated in disease pathogenesis may offer novel therapeutic strategies for mitigating vision loss and preserving retinal function.

Moving forward, continued research is needed to further elucidate the molecular mechanisms underlying metabolic dysregulation in neuro-retinal diseases and evaluate the efficacy and safety of targeted interventions aimed at restoring metabolic balance. Collaborative efforts between basic scientists, clinicians, and industry partners are essential for translating research findings into clinical practice and improving outcomes for patients with neuro-retinal diseases. In summary, the investigation of amino acid and sphingolipid metabolism in acquired neuro-retinal diseases represents a promising avenue for advancing our understanding of disease pathogenesis and developing innovative approaches for diagnosis and treatment. By targeting metabolic dysregulation, we may ultimately improve the lives of individuals affected by these debilitating conditions and reduce the global burden of vision impairment and blindness.

Acknowledgement

None

Conflict of Interest

None

1. Maamari J, Yeung SCJ, Chaftari PS (2019) Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med 37: 376.

Indexed at, Google Scholar, Crossref

2. Haas NL, Gianchandani RY, Gunnerson KJ, Bassin BS, Ganti A, et al. (2018) The two-bag method for treatment of diabetic ketoacidosis in adults. J Emerg Med 54: 593-599.

Indexed at, Google Scholar, Crossref

3. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, et al. (2019) Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord 19: 144.

Indexed at, Google Scholar, Crossref

4. Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, et al. (2021) Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med 50: 335-344.

Indexed at, Google Scholar, Crossref

5. Mae S, Kuriyama A, Tachibana H (2021) Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med 60: 342-344.

Indexed at, Google Scholar, Crossref

6. Godwin Jl, Jaggi S, Sirisena I, Sharda P, Rao AD, et al. (2017) Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunothe Cancer 5: 40.

Indexed at, Google Scholar, Crossref

7. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32: 1335-1343.

Indexed at, Google Scholar, Crossref

8. Puls HA, Haas NL, Franklin BJ, Theyyunni N, Harvey CE, et al. (2021) Euglycemic diabetic ketoacidosis associated with SGLT2i use: case series. Am J Emerg Med 44: 11-13.

Indexed at, Google Scholar, Crossref

9. Kotwal A, Haddox C, Block M, Yogish C, Kudva YC, et al. (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res and Care 7: e000591.

Indexed at, Google Scholar, Crossref

10. Nikouline A, Brzozowski M (2021) New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report. CJEM 23: 712-714.

Indexed at, Google Scholar, Crossref